Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Clinical Practice: Mini-Review

Free Access

Drug Discovery to Halt the Progression of Acute Kidney Injury to Chronic Kidney Disease: A Case for Phenotypic Drug Discovery in Acute Kidney Injury

Hukriede N.a, b · Vogt A.c, d · de Caestecker M.e

Author affiliations

aDepartment of Developmental Biology, bCenter for Critical Care Nephrology, cDepartment of Computational and Systems Biology, and dDrug Discovery Institute, University of Pittsburgh, Pittsburgh, PA, and eDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

Corresponding Author

Dr. Mark de Caestecker

Nephology Division

Vanderbilt University Medical Center, S3223, Medical Center North

1161 21 Street Avenue South Nashville, TN 37232 (USA)

E-Mail mark.de.caestecker@vanderbilt.edu

Related Articles for ""

Nephron 2017;137:268–272

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Abstract

The cellular responses that occur following acute kidney injury (AKI) are complex and dynamic, involving multiple cells types and molecular pathways. For this reason, early selection of defined molecular targets for therapeutic intervention is unlikely to be effective in complex in vivo models of AKI, let alone Phase 3 clinical trials in patients with even more complex AKI pathobiology. Phenotypic screening using zebrafish provides an attractive alternative that does not require prior knowledge of molecular targets and may identify compounds that modify multiple targets that might be missed in more traditional target-based screens. In this review, we discuss results of an academic drug discovery campaign that used zebrafish as a primary screening tool to discover compounds with favorable absorption, metabolism, and toxicity that enhance repair when given late after injury in multiple models of AKI. We discuss how this screening campaign is being integrated into a more comprehensive, phenotypic, and target-based screen for lead compound optimization.

© 2017 S. Karger AG, Basel


References

  1. Coca SG, Singanamala S, Parikh CR: Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 2012;81:442-448.
  2. Lo LJ, Go AS, Chertow GM, et al: Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int 2009;76:893-899.
  3. Wald R, Quinn RR, Luo J, et al: Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA 2009;302:1179-1185.
  4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
  5. Faubel S, Chawla LS, Chertow GM, Goldstein SL, Jaber BL, Liu KD: Ongoing clinical trials in AKI. Clin J Am Soc Nephrol 2012;7:861-873.
  6. Skrypnyk NI, Siskind LJ, Faubel S, de Caestecker MP: Bridging translation for acute kidney injury with better preclinical modeling of human disease. Am J Physiol Renal Physiol 2016;310:F972-F984.
  7. Humphreys BD, Cantaluppi V, Portilla D, et al: Targeting endogenous repair pathways after AKI. J Am Soc Nephrol 2016;27:990-998.
  8. Swinney DC, Anthony J: How were new medicines discovered? Nat Rev Drug Discov 2011;10:507-519.
  9. Okusa MD, Rosner MH, Kellum JA, Ronco C; Acute Dialysis Quality Initiative XIII Workgroup: Therapeutic targets of human AKI: harmonizing human and animal AKI. J Am Soc Nephrol 2016;27:44-48.
  10. Strange K: Drug discovery in fish, flies, and worms. ILAR J 2016;57:133-143.
  11. Giacomotto J, Segalat L: High-throughput screening and small animal models, where are we? Br J Pharmacol 2010;160:204-216.
  12. Lee JA, Berg EL: Neoclassic drug discovery: the case for lead generation using phenotypic and functional approaches. J Biomol Screen 2013;18:1143-1155.
  13. MacRae CA, Peterson RT: Zebrafish as tools for drug discovery. Nat Rev Drug Discov 2015;14:721-731.
  14. Detrich HW 3rd, Westerfield M, Zon LI: Overview of the zebrafish system. Methods Cell Biol 1999;59:3-10.
  15. Williams CH, Hong CC: Zebrafish small molecule screens: taking the phenotypic plunge. Comput Struct Biotechnol J 2016;14:350-356.
  16. Wingert RA, Davidson AJ: The zebrafish pronephros: a model to study nephron segmentation. Kidney Int 2008;73:1120-1127.
  17. Swanhart LM, Cosentino CC, Diep CQ, Davidson AJ, de Caestecker M, Hukriede NA: Zebrafish kidney development: basic science to translational research. Birth Defects Res C Embryo Today 2011;93:141-156.
  18. de Groh ED, Swanhart LM, Cosentino CC, et al: Inhibition of histone deacetylase expands the renal progenitor cell population. J Am Soc Nephrol 2010;21:794-802.
  19. Cianciolo Cosentino C, Roman BL, Drummond IA, Hukriede NA: Intravenous microinjections of zebrafish larvae to study acute kidney injury. J Vis Exp 2010;42:pii:2079.
  20. Cianciolo Cosentino C, Skrypnyk NI, Brilli LL, et al: Histone deacetylase inhibitor enhances recovery after AKI. J Am Soc Nephrol 2013;24:943-953.
  21. Skrypnyk NI, Harris RC, de Caestecker MP: Ischemia-reperfusion model of acute kidney injury and post injury fibrosis in mice. J Vis Exp 2013;78.
  22. Novitskaya T, McDermott L, Zhang KX, et al: A PTBA small molecule enhances recovery and reduces postinjury fibrosis after aristolochic acid-induced kidney injury. Am J Physiol Renal Physiol 2014;306:F496-F504.
  23. Vogt A, Cholewinski A, Shen X, et al: Automated image-based phenotypic analysis in zebrafish embryos. Dev Dyn 2009;238:656-663.
  24. Sanker S, Cirio MC, Vollmer LL, et al: Development of high-content assays for kidney progenitor cell expansion in transgenic zebrafish. J Biomol Screen 2013;18:1193-1202.
  25. Skrypnyk NI, Sanker S, Skvarca LB, et al: Delayed treatment with PTBA analogs reduces postinjury renal fibrosis after kidney injury. Am J Physiol Renal Physiol 2016;310:F705-F716.
  26. Schenone M, Dancik V, Wagner BK, Clemons PA: Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol 2013;9:232-240.
  27. Schenk H, Muller-Deile J, Kinast M, Schiffer M: Disease modeling in genetic kidney diseases: zebrafish. Cell Tissue Res 2017, Epub ahead of print.
  28. Morizane R, Lam AQ, Freedman BS, Kishi S, Valerius MT, Bonventre JV: Nephron organoids derived from human pluripotent stem cells model kidney development and injury. Nat Biotechnol 2015;33:1193-1200.

Article / Publication Details

First-Page Preview
Abstract of Clinical Practice: Mini-Review

Received: April 19, 2017
Accepted: April 24, 2017
Published online: June 15, 2017
Issue release date: Published online first

Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 0

ISSN: 1660-8151 (Print)
eISSN: 2235-3186 (Online)

For additional information: https://www.karger.com/NEF


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.